Therefore, to fully exploit their therapeutic potential, novel approaches are being developed that generally aim to confine 4-1BB costimulation to the TME and draining lymph nodes by adding tumor-specific moieties to generate bispecific 4-1BB agonistic antibodies [8,9,10]. Here, TNFRSF9 is linked to neoplasm.